Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SLA.0000000000005580 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the performance of ChatGPT and ERNIE Bot in answering questions regarding liver cancer interventional radiology in Chinese and English contexts: A comparative study.
Digit Health
January 2025
Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Introduction: This study aims to critically assess the appropriateness and limitations of two prominent large language models (LLMs), enhanced representation through knowledge integration (ERNIE Bot) and chat generative pre-trained transformer (ChatGPT), in answering questions about liver cancer interventional radiology. Through a comparative analysis, the performance of these models will be evaluated based on their responses to questions about transarterial chemoembolization and hepatic arterial infusion chemotherapy in both English and Chinese contexts.
Methods: A total of 38 questions were developed to cover a range of topics related to transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC), including foundational knowledge, patient education, and treatment and care.
Transesophageal echocardiography monitoring for liver transplantation: where are we now?
Minerva Anestesiol
January 2025
Transplant Anesthesia and Critical Care, Pisa NHS and University Hospitals, Pisa, Italy -
Intraoperative hemodynamic monitoring is crucial for managing patients with end-stage liver disease (ESLD) undergoing orthotopic liver transplantation (OLT) due to their complex cardiovascular and pulmonary abnormalities. Traditionally, pulmonary artery catheterization (PAC) has been the standard for hemodynamic monitoring during OLT. However, the use of transesophageal echocardiography (TEE) has increased due to its real-time visualization of cardiac and vascular structures, which aids in managing hemodynamic instability during the three surgical phases of OLT: pre-anhepatic, anhepatic, and neo-hepatic.
View Article and Find Full Text PDFPost-Transplant Lymphoproliferative Disorder at the Porta Hepatis Causing Hepatic Artery Stenosis and Cholestasis.
Am J Case Rep
January 2025
Division of Transplant Surgery, Department of Surgery, University of Virginia School of Medicine, UVA Health, Charlottesville, VA, USA.
BACKGROUND Post-transplant lymphoproliferative disorder (PTLD) encompasses a group of disorders ranging from hyperplastic to malignant lymphoid proliferations in the post-transplant period owing to immunosuppression, often in the setting of EBV transformation. PTLD is a rare complication of immunosuppression that, like lymphomas, can have a variable presentation based on disease localization. We report a case of PTLD mass effect at the porta hepatis for the first time in the literature, resulting in hepatic artery stenosis (HAS) and common hepatic duct obstruction.
View Article and Find Full Text PDFPerioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model.
Sci Rep
January 2025
Institute for Clinical and Experimental Surgery, Saarland University, 66421, Homburg, Germany.
Cilostazol has previously been shown to reduce liver steatosis and enhance hepatic perfusion. We investigated the effects of cilostazol after major hepatectomy in a steatotic rat model. Six weeks prior to surgery, Sprague-Dawley rats were fed with a high-fructose diet.
View Article and Find Full Text PDFEfficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis.
Front Pharmacol
January 2025
Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Purpose: The present work focused on assessing whether hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab was safe and effective on advanced hepatocellular carcinoma (HCC) showing high tumor burden.
Methods: In the present multicenter retrospective study, treatment-naive advanced HCC patients (BCLC stage C) showing high tumor burden (maximum diameter of intrahepatic lesion beyond 7 cm) treated with lenvatinib and tislelizumab with or without HAIC were reviewed for eligibility from June 2020 to June 2023. Baseline differences between groups were mitigated by propensity score matching (PSM).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!